The mission of DTS is the rapid completion of pilot, imaging, and pharmacodynamics-intensive trials tailored to make early, informed decisions regarding the suitability of novel molecular targets and compounds for detailed clinical investigation. DTS clinicians, research nurses, and support staff have extensive experience with early-phase combination and single-agent studies and provide outstanding clincal care for patients with advanced malignancies. In the last four years, DTS has conducted more than 20 early-phase clinical trials which have resulted in a number of publications. DTS is the coordinating site for several multicenter trials open at leading drug development centers across the US.
|Kelly, Ronan J; Rajan, Arun; Force, Jeremy et al. (2011) Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib. Clin Cancer Res 17:1190-9|
|Jain, Lokesh; Woo, Sukyung; Gardner, Erin R et al. (2011) Population pharmacokinetic analysis of sorafenib in patients with solid tumours. Br J Clin Pharmacol 72:294-305|
|Kummar, Shivaani; Gutierrez, Martin E; Gardner, Erin R et al. (2010) Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur J Cancer 46:340-7|
|Jain, Lokesh; Sissung, Tristan M; Danesi, Romano et al. (2010) Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res 29:95|
|Gutierrez, Martin E; Kummar, Shivaani; Giaccone, Giuseppe (2009) Next generation oncology drug development: opportunities and challenges. Nat Rev Clin Oncol 6:259-65|
|Kummar, Shivaani; Doroshow, James H; Tomaszewski, Joseph E et al. (2009) Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies. Eur J Cancer 45:741-6|